Evaluate the avidity of T cells engaged by cell engagers

Part of: Cell engagers

Evaluate the avidity of T cells engaged by cell engagers

Cell engagers (CE) are molecules that can steer immune cells, such as T cells, NK cells, and macrophages, towards cancer cells. Most CEs are bispecific antibodies (BsAb), powerful tools adopted by immuno-oncology that can enhance the recruitment of T cells to specific cancer cells. They facilitate the formation of the immunological synapses (IS), which are key for a proper T-cell response against target cancer cells.

The z-Movi® Cell Avidity Analyzer, specialized in measuring avidity between immune cells and their targets, expands the set of parameters to select the best antibodies for optimal T-cell responses. Using avidity to screen and rank a panel of CEs against the same target, it is possible to find the most potent candidate within a few hours, with clear and reproducible results. Furthermore, the precise control of CE concentration offered by the z-Movi enables researchers to determine the impact of CE concentration on physiological IS formation. Overall, combining cell avidity analysis with the use of BsAbs provides a powerful approach for enhancing T-cell responses against cancer cells.

Quantifying IS formation in the presence of BsAbs as a predictor for in vivo functionality 

In a study by Skokos et al. published in Science Translational Medicine (2020), the authors quantified IS formation in the presence or absence of BsAb to assess anti-tumor efficacy.  In the presence of BsAbs, artificial IS formation was found to be enhanced, resulting in reduced tumor burden (Figure 1). In vivo functionality can thus be predicted by quantifying IS formation in the presence of BsAbs. 

Although fruitful, the methods used in this study to quantify IS formation, such as confocal microscopy and immunofluorescent staining, were time-consuming, low throughput, laborious, and prone to “cherry picking” problems (i.e., bias selection of data sets to show a desired outcome). Measuring cell avidity can help overcome these problems and provide fast, robust, and reproducible results with just one simple assay. In one run, cell avidity measurements can quantify the binding of thousands of T cells to examine the influence of CEs on T-cell engagement on target cells. 

bsabs enhancing

Ranking cell engagers using cell avidity

Cell avidity is a crucial parameter that can be used to screen a panel of CEs against the same target, as it can detect clear and reproducible differences between them. Cell avidity measurement is a simple, robust, fast, and reproducible assay that provides results in just a few hours, in contrast to the lengthy in vitro assays traditionally used. Results obtained by measuring cell avidity have been found to correlate with in vitro cytotoxic assays performed by our collaborators.  

By quantifying cell avidity, the impact of CEs on the initial cell-to-cell binding event can be determined, enabling researchers to rank CEs based on their avidity (Figure 2). Notably, increasing CE avidity has been shown to correlate with improved functionality.  

Cell Engager Avidity
Cell Engager Avidity

Figure 2: Cell engagers can be successfully and reproducibly ranked using cell avidity 

Workflow for establishing BsAb maximum activity (Emax) using cell avidity  

Avidity is a crucial factor in the binding between target and effector cells in the development of CEs. 

To precisely control CE concentrations and accurately represent physiological binding between target and effector cells in a microfluidic chip, we developed a co-injection workflow method (Figure 3). Through titration, we can establish a bell-shaped curve that identifies a window of maximum activity for each BsAb, as previously demonstrated by Betts and van der Graaf. Notably, using this method we demonstrated that excessive or inadequate CE concentrations can have a negative impact on the binding avidity between T cells and their target.  

These findings emphasize the importance of cell avidity measurements in establishing the optimal CE concentration for better immunotherapy treatments. 

Avidity data obtained from a nondisclosed biotech. 

Cell engagers mixed with immune cells
Cell Engager Emax

Betts and van der Graaf et al., 2020, Clin. Pharm. & Ter.

Cell Engager bsAb2
Cell Engager bsAb2

What are some obstacles faced when testing CEs and how do we overcome them?

Conventional Assay

Avidity Assay

Functional assays (e.g., killing, cytokine secretion, etc.) are time-consuming, laborious, and complex

Simple workflow, fast and robust

End-point assays mostly provide bulk information

Provides data at a singlecell resolution in real-time

Highly variable and inconsistent results obtained from traditional in vitro studies

Highly reproducible data

Legacy assays quantify the outcome of T-cell engagement and, therefore, neglect the initial cell-to-cell binding event formed by the bridging of CEs

Cell avidity quantifies the immunological synapse strength between a T cell and target cell in the presence of CEs. Measuring the initial cell-to-cell binding event provides more sensitive measurements, enabling researchers to distinguish subtle differences between CEs during preclinical studies

Difficult to identify lead CE candidates that demonstrate both potent and safe responses in vivo

Measures the avidity of live T cells to live healthy or cancerous cell targets in the presence of CEs. This application improves the ability to find optimal lead CE candidates by quantifying the physiological cell binding to find CEs that are potent but maintain safe profiles for their target. CE candidates can be ranked based on their avidity

CE concentration directly influences functionality, with a bell-shaped trend observed with increasing concentration vs. Emax (maximum functionality)

Assay enables precise control of bispecific concentration conditions within the microfluidic chip. This enables researchers to determine the impact of antibody concentration on physiological cell-to-cell interactions using different CEs and cell models

Conventional Assay

Functional assays (e.g., killing, cytokine secretion, etc.) are time-consuming, laborious, and complex

End-point assays mostly provide bulk information

Highly variable and inconsistent results obtained from traditional in vitro studies

Legacy assays quantify the outcome of T cell engagement and, therefore, neglect the initial cell-to-cell binding event formed by the bridging of CEs

Difficult to identify lead CE candidates that demonstrate both potent and safe responses in vivo

CE concentration directly influences functionality, with a bell-shaped trend observed with increasing concentration vs. Emax (maximum functionality)

Avidity assay 

Simple workflow, fast and robust

Provides data at a singlecell resolution in real-time 

Highly reproducible data 

Cell avidity quantifies the immunological synapse strength between a T cell and target cell in the presence of CEs. Measuring the initial cell-to-cell binding event provides more sensitive measurements, enabling researchers to distinguish subtle differences between CEs during preclinical studies

Measures the avidity of live T cells to live healthy or cancerous cell targets in the presence of CEs. This application improves the ability to find optimal lead CE candidates by quantifying the physiological cell binding to find CEs that are potent but maintain safe profiles for their target. CE candidates can be ranked based on their avidity

Assay enables precise control of bispecific concentration conditions within the microfluidic chip. This enables researchers to determine the impact of antibody concentration on physiological cell-to-cell interactions using different CEs and cell models

Our solutions

z-Movi®

The z-Movi® is a unique instrument that measures the avidity between immune cells and their targets, enabling you to identify the most potent immunotherapeutic effector cells. This new technology provides you with predictive, reproducible, and fast high-throughput results at a single-cell resolution without compromising cell viability. All within a compact little box that easily fits inside the flow hood for sterile and safe sample handling

Book a meeting with an expert today!

Download the brochure to learn more

Join our mailing list

I would like to receive exclusive news about the latest product developments, dynamic single-molecule and immuno-oncology events and breakthrough science. I can revoke my consent at any time.

By submitting the form you agree to LUMICKS' privacy policy.

For pricing, reach out to your application scientist or account manager

Open Email

Fill in our contact form, we will reach out to you!

Please include ‘Lakeview data analysis price inquiry’ in the Message box

Contact Us


Join our newsletter

Get exclusive news on the latest publications, product developments, events and breakthrough science.

By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.

Download our webinar recording:

 

Download our Cell Therapy (CAR-T, TCR, NK) applications deck